Cargando…
Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is considered one of the deadliest tumors worldwide. The diagnosis is often possible only in the latter stages of the disease, with patients already presenting an advanced or metastatic tumor. It is also one of the cancers with poorest prognosis, presenting a...
Autores principales: | Rebelo, Rita, Polónia, Bárbara, Santos, Lúcio Lara, Vasconcelos, M. Helena, Xavier, Cristina P. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003696/ https://www.ncbi.nlm.nih.gov/pubmed/33804613 http://dx.doi.org/10.3390/ph14030280 |
Ejemplares similares
-
Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities
por: Myo Min, Kay K., et al.
Publicado: (2023) -
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
por: Luchini, Claudio, et al.
Publicado: (2020) -
Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities
por: Jain, Aditi, et al.
Publicado: (2021) -
Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma
por: Trestini, Ilaria, et al.
Publicado: (2021) -
Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma
por: Weng, Ningna, et al.
Publicado: (2022)